Medulloblastoma: Molecular Classification and Prognosis

Status: draft · Last updated 2026-11-11 · By Jason S. Hauptman, MD, PhD (AI-assisted)

Read in the interactive book →

High-yield points

  • Four groups: WNT, SHH, Group 3, Group 4 .
    • WHO 2021: WNT-activated; SHH TP53-wildtype; SHH TP53-mutant; non-WNT/non-SHH .
    • Histology (classic, desmoplastic/nodular, MBEN, large cell/anaplastic) is now a morphologic pattern .
  • WNT:
    • CTNNB1 mutation and monosomy 6.
    • Over 90% survival.
    • A candidate for therapy de-escalation .
  • SHH:
    • Infants and adults; PTCH1, SUFU, SMO.
    • TP53 mutation means very high risk (41% 5-year OS) and is often germline .
  • Group 3:
    • MYC amplification; often metastatic.
    • Worst outcome. Metastatic Group 3 is very high risk .
  • Group 4:
    • The most common group (about 46%); i17q.
    • Non-metastatic with chromosome 11 loss or 17 gain is low risk .
  • Genetics referral: test germline in all WNT and SHH tumors .

Landmark papers

  • 2010 consensus (Taylor et al., Acta Neuropathol 2012): defined four core groups, WNT, SHH, Group 3 and Group 4, by transcriptional profiling .
  • 2015 risk-stratification consensus (Ramaswamy et al., Acta Neuropathol 2016): for ages 3–17, low-risk groups have survival over 90% (WNT; non-metastatic Group 4 with chromosome 11 loss or 17 gain) and high-risk groups 50–75% .
  • SJMB03 (Gajjar et al., J Clin Oncol 2021): 330 patients aged 3–21 years. Combining molecular and clinical factors defined three low-risk groups, each with 5-year PFS over 90% .

Medulloblastoma is not one disease. Since a 2010 consensus, it has been divided into four molecular groups: WNT, SHH, Group 3 and Group 4. Each has its own genetics, ages, metastatic behavior and outcome . The 2021 WHO classification builds these groups into the diagnosis. Risk stratification now combines molecular group with the classic clinical factors: age, metastases and extent of resection .

Jason S. Hauptman, MD, PhD© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure from Hauptman's High Yield Thoughts in Pediatric Neurosurgery (pedsneurosurg.org). Do not copy, reproduce, redistribute or adapt without written permission.https://www.pedsneurosurg.org/hy-peds-ns:mb_subgroups:915e3c972aac5f33© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure; please do not copy, reproduce or redistribute without written permission.Summary of the four medulloblastoma molecular subgroups, WNT, SHH, Group 3 and Group 4: frequency, key genetic alterations, age, metastasis at diagnosis and prognosis, with the WHO 2021 typesMEDULLOBLASTOMA: MOLECULAR SUBGROUPSfrequency, ages 3–21 years (SJMB03, methylome)WNT 17.4%SHH 15.7%Group 3 21.3%Group 4 45.6%WNTKEY ALTERATIONSCTNNB1 mutation (96%)monosomy 6AGEchildren and adults;uncommon in infantsMETASTATIC AT DIAGNOSIS9%PROGNOSISexcellent:>90% long-term survivalSHHKEY ALTERATIONSPTCH1 / SUFU / SMOTP53 (germline TP53 inolder children)MYCN amplificationAGEbimodal: infants (0–3)and adults (>16)METASTATIC AT DIAGNOSISinfants 17%, children 22%,rare in adultsPROGNOSISvaries with TP53: 5-yr OS81% wild-type vs41% mutantGroup 3KEY ALTERATIONSMYC amplificationisochromosome 17q (26%)AGEinfants and children;almost never adultsMETASTATIC AT DIAGNOSIS30%PROGNOSISworst: 5-yr OS 58%in children, 45%in infantsGroup 4KEY ALTERATIONSisochromosome 17q (66%;the most common change)MYCN amplificationin someAGEclassic childhood(prototype: a 7-year-oldboy)METASTATIC AT DIAGNOSIS31%PROGNOSISintermediateWHO 2021 types:WNT-activated; SHH-activated, TP53-wild-type; SHH-activated, TP53-mutant;non-WNT/non-SHH (Groups 3 and 4).Metastasis rates from the Kool meta-analysis; OS, overall survival.
Summary of the four molecular groups of medulloblastoma: frequency in children 3–21 years (SJMB03), key genetic alterations, age pattern, metastasis at diagnosis and prognosis, with the corresponding 2021 WHO types. Numbers are from the cited series.

Classification

The four groups

Prognostic implications

Germline predisposition

Targeted therapy

Related topics

References

  1. Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012;123(4):465–472. doi:10.1007/s00401-011-0922-z. PMID 22134537. verified
  2. Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 2012;123(4):473–484. doi:10.1007/s00401-012-0958-8. PMID 22358457. verified
  3. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23(8):1231–1251. doi:10.1093/neuonc/noab106. PMID 34185076. verified
  4. Ramaswamy V, Remke M, Bouffet E, et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol 2016;131(6):821–831. doi:10.1007/s00401-016-1569-6. PMID 27040285. verified
  5. Cavalli FMG, Remke M, Rampasek L, et al. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell 2017;31(6):737–754.e6. doi:10.1016/j.ccell.2017.05.005. PMID 28609654. verified
  6. Sharma T, Schwalbe EC, Williamson D, et al. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. Acta Neuropathol 2019;138(2):309–326. doi:10.1007/s00401-019-02020-0. PMID 31076851. verified
  7. Gajjar A, Robinson GW, Smith KS, et al. Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an international phase III trial (SJMB03). J Clin Oncol 2021;39(7):822–835. doi:10.1200/JCO.20.01372. PMID 33405951. verified
  8. Zhukova N, Ramaswamy V, Remke M, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 2013;31(23):2927–2935. doi:10.1200/JCO.2012.48.5052. PMID 23835706. verified
  9. Schwalbe EC, Lindsey JC, Nakjang S, et al. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet Oncol 2017;18(7):958–971. doi:10.1016/S1470-2045(17)30243-730243-7). PMID 28545823. verified
  10. Waszak SM, Northcott PA, Buchhalter I, et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol 2018;19(6):785–798. doi:10.1016/S1470-2045(18)30242-030242-0). PMID 29753700. verified
  11. Robinson GW, Orr BA, Wu G, et al. Vismodegib exerts targeted efficacy against recurrent sonic hedgehog-subgroup medulloblastoma: results from phase II Pediatric Brain Tumor Consortium studies PBTC-025B and PBTC-032. J Clin Oncol 2015;33(24):2646–2654. doi:10.1200/JCO.2014.60.1591. PMID 26169613. verified

Verification (2026-11-11): each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed. Numbers were checked against the PubMed abstracts and, where needed, the open-access full texts:

Caveats: